DK1299383T3 - Sulfonyl-pyrrolidinderivater, der kan anvendes til behandling af neurologiske lidelser - Google Patents

Sulfonyl-pyrrolidinderivater, der kan anvendes til behandling af neurologiske lidelser

Info

Publication number: DK1299383T3
Authority: DK; Denmark
Prior art keywords: sulfonyl; neurological disorders; pyrrolidine derivatives; treat neurological; compounds
Prior art date: 2000-06-30

Application number

DK01960365T

Other languages

Danish (da)

English (en)

Inventor

Vincent Mutel

Juergen Wichmann

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-30

Filing date

2001-06-22

Publication date

2005-05-23

2001-06-22 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2005-05-23 Application granted granted Critical

2005-05-23 Publication of DK1299383T3 publication Critical patent/DK1299383T3/da

Links

208000012902 Nervous system disease Diseases 0.000 title abstract 2
208000025966 Neurological disease Diseases 0.000 title abstract 2
FDAMVVHYWSPPFN-UHFFFAOYSA-N 2-sulfonylpyrrolidine Chemical class O=S(=O)=C1CCCN1 FDAMVVHYWSPPFN-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 2
108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 2
230000001154 acute effect Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Otolaryngology (AREA)

DK01960365T 2000-06-30 2001-06-22 Sulfonyl-pyrrolidinderivater, der kan anvendes til behandling af neurologiske lidelser DK1299383T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP00113894		2000-06-30
PCT/EP2001/007135 WO2002002554A1 (en)	2000-06-30	2001-06-22	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
EP01960365A EP1299383B1 (de)	2000-06-30	2001-06-22	Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten

Publications (1)

Publication Number	Publication Date
DK1299383T3 true DK1299383T3 (da)	2005-05-23

Family

ID=8169121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01960365T DK1299383T3 (da)	2000-06-30	2001-06-22	Sulfonyl-pyrrolidinderivater, der kan anvendes til behandling af neurologiske lidelser

Country Status (34)

Country	Link
US (2)	US6589978B2 (de)
EP (1)	EP1299383B1 (de)
JP (1)	JP3994051B2 (de)
KR (1)	KR100529423B1 (de)
CN (1)	CN1178936C (de)
AR (1)	AR029288A1 (de)
AT (1)	ATE286895T1 (de)
AU (2)	AU8187701A (de)
BR (1)	BR0112093A (de)
CA (1)	CA2413243A1 (de)
CZ (1)	CZ2003280A3 (de)
DE (1)	DE60108394T2 (de)
DK (1)	DK1299383T3 (de)
EC (1)	ECSP024403A (de)
ES (1)	ES2234869T3 (de)
HR (1)	HRP20021023B1 (de)
HU (1)	HUP0301167A3 (de)
IL (2)	IL153425A0 (de)
JO (1)	JO2384B1 (de)
MA (1)	MA26923A1 (de)
MX (1)	MXPA02012270A (de)
MY (1)	MY126903A (de)
NO (1)	NO324218B1 (de)
NZ (1)	NZ523025A (de)
PE (1)	PE20020103A1 (de)
PL (1)	PL360396A1 (de)
PT (1)	PT1299383E (de)
RU (1)	RU2272026C2 (de)
SI (1)	SI1299383T1 (de)
TW (1)	TWI265928B (de)
UY (1)	UY26812A1 (de)
WO (1)	WO2002002554A1 (de)
YU (1)	YU99702A (de)
ZA (1)	ZA200209966B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7256186B2 (en)	2002-02-06	2007-08-14	Schering Corporation	Gamma secretase inhibitors
TW200302717A (en) *	2002-02-06	2003-08-16	Schering Corp	Novel gamma secretase inhibitors
US20040171614A1 (en) *	2002-02-06	2004-09-02	Schering-Plough Corporation	Novel gamma secretase inhibitors
DE10240818A1 (de) *	2002-08-30	2004-05-13	Grünenthal GmbH	Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
GB0225938D0 (en) *	2002-11-06	2002-12-11	Glaxo Group Ltd	Novel compounds
WO2005097768A2 (en) *	2004-04-05	2005-10-20	Schering Corporation	Novel gamma secretase inhibitors
US20060035884A1 (en) *	2004-05-20	2006-02-16	Elan Pharmaceuticals, Inc.	N-cyclic sulfonamido inhibitors of gamma secretase
PE20060481A1 (es)	2004-06-30	2006-06-19	Schering Corp	N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas
CA2574218A1 (en) *	2004-07-22	2006-02-09	Schering Corporation	Substituted amide beta secretase inhibitors
KR101178747B1 (ko)	2004-09-30	2012-09-03	다케다 야쿠힌 고교 가부시키가이샤	프로톤 펌프 저해제
RU2413510C2 (ru) *	2005-04-04	2011-03-10	Такеда Фармасьютикал Компани Лимитед	Профилактический или терапевтический агент против депрессии или тревожного расстройства
EP2275095A3 (de)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
PE20070540A1 (es)	2005-08-30	2007-06-26	Takeda Pharmaceutical	Derivados de pirrol como inhibidores de la secrecion acida
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (de)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
RU2462464C2 (ru) *	2006-09-29	2012-09-27	Грюненталь Гмбх	Замещенные сульфамидные производные
US8933105B2 (en)	2007-02-28	2015-01-13	Takeda Pharmaceutical Company Limited	Pyrrole compounds
ES2572615T3 (es) *	2008-08-15	2016-06-01	Nivalis Therapeutics, Inc.	Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
UA105185C2 (uk)	2008-08-27	2014-04-25	Такеда Фармасьютікал Компані Лімітед	Піроли
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
ES2351323B1 (es) *	2009-06-26	2011-10-05	Institut Univ. De Ciència I Tecnologia, S.A.	Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
ES2351452B1 (es) *	2009-07-01	2011-10-05	Institut Univ. De Ciència I Tecnologia, S.A.	Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
US20240327392A1 (en) *	2021-06-25	2024-10-03	Albius Sciences Alpha Private Limited	Heterocycloalkyl-substituted polyheteroazole derivatives as medicaments for treating and/or preventing rs virus infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3905979A (en) *	1974-05-09	1975-09-16	Stanford Research Inst	Diazabicyclooctanes and diazabicycloheptanes
US4539411A (en) *	1982-02-05	1985-09-03	Hoffmann-La Roche Inc.	Rhodium complexes of chiral phosphines
US5036153A (en) *	1989-05-11	1991-07-30	Braish Tamim F	Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates
US6417198B1 (en) *	1993-12-21	2002-07-09	Eli Lilly And Company	Methods of inhibiting CNS problems in post-menopausal women
GB9612884D0 (en)	1996-06-20	1996-08-21	Smithkline Beecham Plc	Novel compounds
US5721256A (en)	1997-02-12	1998-02-24	Gpi Nil Holdings, Inc.	Method of using neurotrophic sulfonamide compounds
US6645939B1 (en) *	1997-11-24	2003-11-11	Merck & Co., Inc.	Substituted β-alanine derivatives as cell adhesion inhibitors
AU750175B2 (en)	1997-11-24	2002-07-11	Merck & Co., Inc.	Cyclic amino acid derivatives as cell adhesion inhibitors
GB9804426D0 (en)	1998-03-02	1998-04-29	Pfizer Ltd	Heterocycles
AT411339B (de)	1998-05-13	2003-12-29	Fronius Schweissmasch Prod	Verfahren zum steuern eines schweissgerätes und steuervorrichtung hierfür
HUP0102532A3 (en)	1998-06-03	2002-06-28	Gpi Nil Holdings Inc Wilmingto	Aza-heterocyclic compounds used to treat neurological disorders and hair loss and process for their preparation and pharmaceutical compositions containing them
TR200101754T2 (tr)	1998-12-18	2002-05-21	Schering Corporation	Farnezil protein transferaz inhibitörleri
TR200102766T2 (tr) *	1999-01-27	2001-12-21	Ortho-Mcneil Pharmaceutical, Inc.	Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar
TW575561B (en) *	1999-03-25	2004-02-11	Hoffmann La Roche	1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
JP2003500406A (ja) *	1999-05-20	2003-01-07	ドンワファーマシューティカルズインダストリーコーポレーティッドリミテッド	光学活性を誘発する７−ピロリジン置換体を持った光学活性のキノリンカルボン酸誘導体及びその製造方法
US6143776A (en) *	2000-02-02	2000-11-07	Sunesis Pharmaceuticals, Inc.	Tosylproline analogs as thymidylate synthase inhibitors

2001
- 2001-06-13 US US09/880,539 patent/US6589978B2/en not_active Expired - Fee Related
- 2001-06-14 TW TWSULFONYL-A patent/TWI265928B/zh not_active IP Right Cessation
- 2001-06-22 AU AU8187701A patent/AU8187701A/xx active Pending
- 2001-06-22 CA CA002413243A patent/CA2413243A1/en not_active Abandoned
- 2001-06-22 HU HU0301167A patent/HUP0301167A3/hu unknown
- 2001-06-22 ES ES01960365T patent/ES2234869T3/es not_active Expired - Lifetime
- 2001-06-22 NZ NZ523025A patent/NZ523025A/en unknown
- 2001-06-22 KR KR10-2002-7017967A patent/KR100529423B1/ko not_active Expired - Fee Related
- 2001-06-22 PT PT01960365T patent/PT1299383E/pt unknown
- 2001-06-22 WO PCT/EP2001/007135 patent/WO2002002554A1/en not_active Ceased
- 2001-06-22 PL PL36039601A patent/PL360396A1/xx unknown
- 2001-06-22 DK DK01960365T patent/DK1299383T3/da active
- 2001-06-22 HR HR20021023A patent/HRP20021023B1/xx not_active IP Right Cessation
- 2001-06-22 DE DE60108394T patent/DE60108394T2/de not_active Expired - Fee Related
- 2001-06-22 AU AU2001281877A patent/AU2001281877B2/en not_active Ceased
- 2001-06-22 AT AT01960365T patent/ATE286895T1/de not_active IP Right Cessation
- 2001-06-22 MX MXPA02012270A patent/MXPA02012270A/es active IP Right Grant
- 2001-06-22 BR BR0112093-0A patent/BR0112093A/pt not_active IP Right Cessation
- 2001-06-22 JP JP2002507806A patent/JP3994051B2/ja not_active Expired - Fee Related
- 2001-06-22 CN CNB01812061XA patent/CN1178936C/zh not_active Expired - Fee Related
- 2001-06-22 IL IL15342501A patent/IL153425A0/xx active IP Right Grant
- 2001-06-22 SI SI200130290T patent/SI1299383T1/xx unknown
- 2001-06-22 RU RU2003100516/04A patent/RU2272026C2/ru not_active IP Right Cessation
- 2001-06-22 YU YU99702A patent/YU99702A/sh unknown
- 2001-06-22 CZ CZ2003280A patent/CZ2003280A3/cs unknown
- 2001-06-22 EP EP01960365A patent/EP1299383B1/de not_active Expired - Lifetime
- 2001-06-26 JO JO2001100A patent/JO2384B1/en active
- 2001-06-27 AR ARP010103053A patent/AR029288A1/es not_active Application Discontinuation
- 2001-06-27 PE PE2001000638A patent/PE20020103A1/es not_active Application Discontinuation
- 2001-06-27 MY MYPI20013048 patent/MY126903A/en unknown
- 2001-06-29 UY UY26812A patent/UY26812A1/es not_active Application Discontinuation
2002
- 2002-12-09 ZA ZA200209966A patent/ZA200209966B/en unknown
- 2002-12-12 IL IL153425A patent/IL153425A/en not_active IP Right Cessation
- 2002-12-26 EC EC2002004403A patent/ECSP024403A/es unknown
- 2002-12-27 NO NO20026263A patent/NO324218B1/no unknown
- 2002-12-27 MA MA26983A patent/MA26923A1/fr unknown
2003
- 2003-03-26 US US10/397,908 patent/US6995182B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2234869T3 (es)	2005-07-01
PE20020103A1 (es)	2002-02-13
DE60108394T2 (de)	2006-03-02
KR100529423B1 (ko)	2005-11-17
HRP20021023B1 (en)	2006-08-31
AR029288A1 (es)	2003-06-18
NO324218B1 (no)	2007-09-10
US20030212066A1 (en)	2003-11-13
PT1299383E (pt)	2005-05-31
PL360396A1 (en)	2004-09-06
IL153425A (en)	2007-08-19
AU2001281877B2 (en)	2006-08-31
HK1058358A1 (en)	2004-05-14
ZA200209966B (en)	2004-03-09
DE60108394D1 (de)	2005-02-17
YU99702A (sh)	2006-05-25
JP3994051B2 (ja)	2007-10-17
UY26812A1 (es)	2001-12-28
ECSP024403A (es)	2003-02-06
US6995182B2 (en)	2006-02-07
RU2272026C2 (ru)	2006-03-20
US20020019424A1 (en)	2002-02-14
BR0112093A (pt)	2003-05-13
MA26923A1 (fr)	2004-12-20
WO2002002554A1 (en)	2002-01-10
US6589978B2 (en)	2003-07-08
CZ2003280A3 (cs)	2003-12-17
CN1178936C (zh)	2004-12-08
HUP0301167A2 (hu)	2003-08-28
CN1440405A (zh)	2003-09-03
EP1299383B1 (de)	2005-01-12
HUP0301167A3 (en)	2009-12-28
CA2413243A1 (en)	2002-01-10
IL153425A0 (en)	2003-07-06
KR20030011378A (ko)	2003-02-07
MY126903A (en)	2006-10-31
AU8187701A (en)	2002-01-14
SI1299383T1 (en)	2005-06-30
JP2004502688A (ja)	2004-01-29
MXPA02012270A (es)	2003-04-25
ATE286895T1 (de)	2005-01-15
EP1299383A1 (de)	2003-04-09
NO20026263L (no)	2002-12-27
NZ523025A (en)	2004-04-30
JO2384B1 (en)	2007-06-17
NO20026263D0 (no)	2002-12-27
TWI265928B (en)	2006-11-11
HRP20021023A2 (en)	2004-08-31

Publication	Publication Date	Title
DK1299383T3 (da)	2005-05-23	Sulfonyl-pyrrolidinderivater, der kan anvendes til behandling af neurologiske lidelser
ATE337780T1 (de)	2006-09-15	Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
BR0313265A (pt)	2005-07-05	Compostos e respectivos processos de preparação, uso e formulações farmacêuticas e métodos de prevenção e/ou tratamento de distúrbios mediados por receptor mglur5 e de inbição da ativação de receptores mglu r5.
BRPI0407993B8 (pt)	2021-05-25	compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
MXPA04004064A (es)	2004-09-06	Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
PE20020521A1 (es)	2002-07-15	Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
JO2285B1 (en)	2005-09-12	Dihydro-benzoic derivatives
AP2001002318A0 (en)	2001-12-31	Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2002036562A3 (en)	2003-01-23	1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
BR0308787A (pt)	2005-01-11	Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
PL372809A1 (en)	2005-08-08	Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
BG66084B1 (bg)	2011-03-31	Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
BG104138A (en)	2000-11-30	2-aminopyridines containing substituents with condensed rings as nos inhibitors
JO2273B1 (en)	2005-04-07	Dihydro-benzo derivatives [B] [1.4] di-azin-2-one
NO20060328L (no)	2006-02-17	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
ATE301995T1 (de)	2005-09-15	Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
BR9911060A (pt)	2001-02-06	Composições compreendendo mono- ou dinitrato orgânico para tratar impotência
DK1456380T3 (da)	2012-07-30	SMAD7-inhibitorer til behandling af CNS-sygdomme
WO2002051832A3 (en)	2002-09-06	Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
MY139498A (en)	2009-10-30	Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
DE69838882D1 (de)	2008-01-31	Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DK1463735T3 (da)	2009-12-14	Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
EA200300040A1 (ru)	2003-06-26	1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов
UY26426A1 (es)	2001-05-31	Nuevos compuestos